Perte: Pertuzumab For The Neoadjuvant Treatment Of Her2-Positive Breast Cancer Patients-Efficacy And Safety Of Pertuzumab In "Real Life" Setting.

e12654Background: Standard preoperative systemic therapy for HER2+ breast cancer (BC) patients (pts) includes chemotherapy (CT) and Trastuzumab (T). Two randomized phase II trials, NeoSphere and TRYPHAENA, showed that the addition of Pertuzumab (P) to a T–based neoadjuvant therapy improves the pathologic complete response (pCR) rate, with no evidence that P increased the rate of cardiac dysfunction. Based on these two trials, on June 2015, European Medicine Agency (EMA) approved dual HER2 blockade with T+P for the neoadjuvant treatment of HER2+ BC. PerTe is an observational study, aimed to evaluate the efficacy and safety of P+T as neoadjuvant treatment of HER2+ BC in a real practice setting. Methods: 65 pts treated with P+T+CT as neoadjuvant therapy were identified by 3 Italian Institutions since July 2015. Based on clinical practice of belonging institution, pts were treated with 3 different CT regimens: 1) ECx4 followed by P+T+weekly paclitaxel for 12, 2) ECx4 followed by P+T+docetaxel for 4 cycles and...